Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study)
Pharmaceuticals · 11.05.2026 · 19 (5) · 747
DOI: 10.3390/ph19050747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 11.05.2026. Verfasst von Debdulal Chakraborty und 9 weiteren Autor:innen. Beteiligte Einrichtung: Disha Eye Hospitals, Kolkata 700029, India. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV), often require repeated intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. Although ranibizumab is well established, long-term affordability remains challenging.
Objective
To compare the functional, anatomical, treatment-burden, and safety outcomes of biosimilar ranibizumab (Ranieyes) and innovator ranibizumab (Lucentis/Accentrix) in routine clinical practice.
Methods
This multicenter retrospective comparative study included 4997 eyes from 3577 patients treated across five tertiary eye-care centers in India. The biosimilar group comprised 2543 eyes from 1812 patients (10,893 injections), and the innovator group comprised 2454 eyes from 1765 patients (10,136 injections). Eligible indications were nAMD, DME, BRVO, CRVO, mCNV, and an exploratory miscellaneous preoperative adjunct subgroup. BCVA (logMAR), central subfield thickness (CST; µm), injection burden, and ocular/systemic adverse events were assessed over 24 months.
Results
Both groups showed early improvement in BCVA and CST across the major disease categories, followed by long-term stabilization. Between-group differences were generally small, not sustained over follow-up, and of limited clinical magnitude. Serious ocular and systemic adverse events were rare in both groups, and no new safety signal emerged.
Conclusions
In this large real-world cohort, the biosimilar ranibizumab Ranieyes showed outcomes broadly comparable to innovator ranibizumab across the major retinal disease subgroups, although these findings should be interpreted as observational comparative evidence rather than formal proof of equivalence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Disha Eye Hospitals, Kolkata 700029, India.
- Nethralayam Superspeciality Eye Hospital, Kolkata 700073, India.
- Global Eye Hospital, Kolkata 700054, India.
- Sankara Jyoti Eye Institute, Kolkata 700060, India.
ORCID-Profile: Debdulal Chakraborty
Zitieren
APA
Chakraborty, D., Sinha, T. K., Sinha, S., Biswas, R. K., Das, A., Maiti, A., Bhattacharya, R., Dan, S., Rungta, D., & Das, S. (2026). Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). Pharmaceuticals, 19(5), 747. https://doi.org/10.3390/ph19050747
Vancouver
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Das A, Maiti A, et al. Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study). Pharmaceuticals. 2026;19(5):747. doi:10.3390/ph19050747
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Debdulal and Sinha, Tushar Kanti and Sinha, Sourav and Biswas, Rupak Kanti and Das, Arnab and Maiti, Aniruddha and Bhattacharya, Ranabir and Dan, Shouvick and Rungta, Dinesh and Das, Shibashis},
title = {Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study)},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {747},
doi = {10.3390/ph19050747}
}
EUVIMED